Welcome to our dedicated page for International Isotopes SEC filings (Ticker: INIS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for International Isotopes Inc. (now Radnostix, Inc., ticker INIS) provide detailed insight into the company’s operations, governance, and strategic direction in the radioisotope and theranostics space. As a Texas-incorporated issuer with its stock quoted on the OTCQB marketplace, the company files periodic and current reports under the Securities Exchange Act of 1934.
On this page, users can review current reports on Form 8-K that document material events. Recent 8-K filings describe the legal name change from International Isotopes Inc. to Radnostix, Inc. through a Certificate of Amendment in Texas, along with the rationale that the new name better reflects the company’s broader portfolio of radioisotope, theranostics, and related products, devices, and accessories. Another 8-K outlines an employment agreement with the company’s President and Chief Executive Officer, including compensation terms and equity incentives, and details amendments to the company’s bylaws covering special meetings, advance notice procedures for shareholder proposals and director nominations, advisory directors, indemnification, and insurance.
Filings also address board composition and governance, such as the appointment of an independent director with nuclear pharmacy and radiopharmaceutical manufacturing experience and that director’s role on the audit committee. These disclosures help investors understand oversight structures, independence considerations, and board-level expertise relevant to the company’s radiopharmaceutical and medical device activities.
In addition to 8-Ks, investors can use this page to access the company’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available), which typically include segment information for Theranostics Products, Calibration & Reference Products, Cobalt Products, Medical Devices, and Fluorine Products, along with risk factors and management’s discussion and analysis. Form 4 and other insider transaction reports, when filed, can shed light on equity awards and share transactions by executives and directors.
Stock Titan’s platform enhances these documents with AI-powered summaries that highlight key points from lengthy filings, explain complex sections in plain language, and surface items related to topics such as governance changes, segment disclosures, and compensation arrangements. Real-time updates from EDGAR help ensure that new INIS filings, including 10-Ks, 10-Qs, 8-Ks, and Forms 3 and 4, are quickly available with contextual AI insights for users analyzing this radioisotope-focused company.
International Isotopes Inc. reported that it has changed its corporate name to Radnostix, Inc. by filing a Certificate of Amendment in Texas on December 23, 2025. The board approved the change on October 21, 2025, and a majority of shareholders approved it by written consent on November 25, 2025.
The company explains that its business has expanded from radiochemicals and non-medical radioisotopes with an energy focus to a broader portfolio of radioisotope, theranostic, and related healthcare products and devices. Management believes the Radnostix, Inc. name better reflects this healthcare-focused direction. The common stock will continue to trade under the ticker "INIS" on the OTCQB, and shareholders do not need to take any action regarding existing stock certificates.
International Isotopes Inc. (INIS) has obtained written consent from shareholders holding approximately 52.1% of its common stock to amend its Certificate of Formation and change its corporate name to Radnostix, Inc. The board of directors unanimously approved the name change on October 21, 2025, and shareholders of record on November 24, 2025, representing 275,232,379 votes out of 528,209,538 outstanding shares, approved it by written consent in lieu of a meeting.
The change reflects a business shift from primarily energy‑sector isotopes toward a broader portfolio of radioisotope, theranostics, and related healthcare products, devices, and accessories. No shareholder meeting or proxy is being solicited. The name change will become effective after the company files a certificate of amendment with the Texas Secretary of State, at least 20 days after this Information Statement is first mailed.
International Isotopes Inc. (INIS) reported Q3 2025 results with sale of product of $3,277,816 and a net loss of $203,601. For the nine months ended September 30, 2025, sale of product was $10,172,036 and net loss was $477,080. Gross margin held near 59% in Q3 as operating expenses declined 7% year over year.
The company advanced its planned divestiture of the Fluorine Products and de‑conversion assets, noting total cash consideration of $12.5 million if the deal closes by the Outside Date of March 31, 2026. On September 30, 2025, INIS and the buyer submitted an application to the NRC to transfer the license; closing remains subject to financing and regulatory approvals.
Theranostics revenue fell on a temporary supplier outage and partial account loss, while Calibration & Reference grew; management cites an additional approved supplier from September. Cash and cash equivalents were $1,651,548 with restricted cash of $1,477,685. INIS disclosed an FDA inspection in April resulting in an OAI; corrective actions have been submitted and manufacturing continues pending reinspection.
International Isotopes Inc. (INIS) approved a new employment agreement for CEO and President Shahe Bagerdjian. The term runs from July 18, 2025 to July 18, 2030, with an initial base salary of $314,000 and automatic 5% annual increases. He may receive additional $50,000 salary increases as quarterly revenue reaches $3.75M, $6.25M, $12.5M, $18.75M, and $25M, excluding one-time other income items.
The agreement grants 37,500,000 RSUs, vesting after the share price is at or above $0.10 (2.5M), $0.15 (5.0M), $0.20 (7.5M), $0.25 (10.0M), and $0.30 (12.5M) for 60 consecutive days and subject to a tax‑withholding cash condition or six months after the trigger date. Unvested RSUs accelerate upon termination without cause or immediately before a change of control while in good standing. He remains eligible for annual cash bonuses set by the Board.
Governance updates: Dr. Duke W. Fu was appointed an independent director and to the audit committee; he will receive 250,000 RSUs per annual term (vesting commencement July 11, 2026). The Board amended bylaws to limit special-meeting business to noticed items, add advance notice for business and director nominations, permit advisory directors, allow shareholder action by less than unanimous written consent, and add indemnification and insurance provisions.
International Isotopes Inc. (INIS) updated leadership agreements and corporate governance. The company entered a new employment agreement with CEO and President Shahe Bagerdjian, effective July 18, 2025, through July 18, 2030, with automatic one-year renewals. His initial annual base salary is $314,000 with automatic 5% yearly increases and potential $50,000 step-ups tied to quarterly revenue milestones at $3.75M, $6.25M, $12.5M, $18.75M, and $25M.
Bagerdjian received 37,500,000 RSUs vesting upon sustained share-price hurdles of $0.10, $0.15, $0.20, $0.25, and $0.30 and specified cash/withholding conditions; unvested RSUs vest upon termination without cause or immediately prior to a change of control if in good standing. A prior 6,500,000 RSU grant remains, with 3,000,000 vesting on April 17, 2026.
The Board appointed Dr. Duke W. Fu as an independent director and audit committee member; compensation includes 250,000 RSUs per annual term starting July 11, 2026. Amended bylaws add advance notice procedures for business and director nominations, clarify special meeting scope and scheduling, permit advisory directors, allow shareholder action by less than unanimous written consent, and add indemnification and insurance provisions.
International Isotopes Inc. (INIS) director reported an equity grant. On 10/10/2025, the insider acquired 250,000 shares of common stock at $0, recorded as a grant of restricted stock units, with each unit representing the right to receive one INIS share. Following the transaction, the insider beneficially owned 1,000,000 shares, held directly.
International Isotopes Inc. (INIS) reported a director received a stock option grant. On 10/10/2025, the reporting person was awarded 500,000 stock options at an exercise price of $0.06 per share, recorded with transaction code A.
The options are first exercisable on 07/11/2026 and expire on 10/10/2035. Following this transaction, the reporting person beneficially owned 500,000 derivative securities, held directly.
International Isotopes Inc. (INIS) reported an insider transaction on a Form 4. A reporting person who is both a Director and 10% Owner was granted a stock option to purchase 500,000 shares of common stock at an exercise price of $0.06 per share on 10/10/2025 (transaction code A).
The option becomes exercisable on 07/11/2026 and expires on 10/10/2035. Following the transaction, the insider beneficially owned 500,000 derivative securities, held directly.
International Isotopes Inc. (INIS) reported an insider equity award on Form 4. President & CEO and director Shahe Bagerdjian received 37,500,000 restricted stock units (RSUs) on October 9, 2025 under the company’s Amended and Restated 2015 Incentive Plan.
Each RSU represents a contingent right to receive one share of INIS common stock. The RSUs vest based on milestones tied to the company’s share price and available cash. Following the transaction, the filing shows 37,500,000 derivative securities beneficially owned, held directly, with a stated price of $0 for the RSUs.
FAQ
What is the current stock price of International Isotopes (INIS)?
What is the market cap of International Isotopes (INIS)?
